TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.

Sponsor: Loxo Oncology, Inc.

You may qualify if…

  • ✓ Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria.
  • ✓ Part 1: Have received prior CLL/SLL treatment
  • ✓ Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL
  • ✓ Have received a covalent BTK inhibitor
  • ✓ Part 2: Have received no prior treatment for CLL/SLL
  • ✓ Part 1 - Known 17p deletion status (positive or negative)
  • ✓ Part 2 - Must have 17p deletion (positive)
  • ✓ Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy

You may not qualify if…

  • ✕ Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor
  • ✕ Have a history of greater than or equal to (\>=) Grade 3 bleeding due to treatment with a BTK inhibitor
  • ✕ Have known or suspected Richter's transformation
  • ✕ Have known or suspected history of central nervous system involvement by CLL/SLL
  • ✕ Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
  • ✕ nonmelanoma skin cancer or lentigo malignant melanoma
  • ✕ cervical carcinoma in situ
  • ✕ localized prostate cancer undergoing active surveillance, and

Where it's recruiting

Arizona

Chandler

California

Duarte · Irvine · Palo Alto

Colorado

Aurora

Florida

Miami

Georgia

Newnan

Iowa

Waukee

Kentucky

Edgewood

Maryland

Bethesda

Mississippi

Gulfport

Nevada

Henderson

North Carolina

Greenville

Source: ClinicalTrials.gov · NCT06588478 · last updated 2026-11-04